| 09/01 | Atea Pharmaceuticals Highlights Strategic Priorities for 2023 |  |
| 09/01 | Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for .. | |
| 04/01 | Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 2022 | Atea Pharmaceuticals Says It Dosed First Patient in Phase 3 Trial of Bemnifosbuvir to T.. | |
| 2022 | Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational .. | |
| 2022 | Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrat.. | |
| 2022 | Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference | |
| 2022 | Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference | |
| 2022 | ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. | |
| 2022 | Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont.. | |
| 2022 | Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business.. | |
| 2022 | Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fev.. | |
| 2022 | Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on No.. | |
| 2022 | Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsigh.. | |
| 2022 | Sector Update: Health Care Stocks Mixed Premarket Monday | |
| 2022 | Sector Update: Health Care | |
| 2022 | Atea Pharmaceuticals Receives FDA Fast Track for Dengue Treatment | |
| 2022 | Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Tr.. | |
| 2022 | Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 .. | |
| 2022 | Atea Gets FDA Fast-Track Designation for AT-752 in Dengue | |
| 2022 | Atea Pharmaceuticals : Bemnifosbuvir Program Update Call Presentation | |
| 2022 | Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-H.. | |
| 2022 | Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbu.. | |
| 2022 | Atea Pharmaceuticals Announces Upcoming Investor Events | |
| 2022 | Atea Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business.. | |
| 2022 | ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. | |
| 2022 | Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Mont.. | |
| 2022 | Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Busines.. | |
| 2022 | Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on A.. | |
| 2022 | Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R.. | |
| 2022 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr.. | |
| 2022 | Atea Pharmaceuticals, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K.. | |
| 2022 | Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference | |
| 2022 | Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, .. | |
| 2022 | ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. | |
| 2022 | Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3.. | |
| 2022 | Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business.. | |
| 2022 | Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma.. | |
| 2022 | 4794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi.. | |
| 2022 | 4793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral.. | |
| 2022 | Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci.. | |
| 2022 | ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. | |
| 2022 | Atea Pharmaceuticals : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro.. | |
| 2022 | Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31.. | |
| 2022 | Atea Pharmaceuticals : Fourth Quarter 2021 Financial Results Conference Call Presentation | |
| 2022 | Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb.. | |
| 2022 | Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Pr.. | |
| 2022 | Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Confer.. | |
| 2022 | Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice Presid.. | |
| 2022 | Atea Pharmaceuticals, Inc. Announces Executive Changes | |
| 2022 | Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference | |
| 2022 | Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir's (AT-527) .. | |
| 2022 | Atea Pharmaceuticals, Inc. Announces Publication of Data Supporting Bemnifosbuvir’.. | |
| 2022 | Atea Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (.. | |
| 2022 | Atea Pharmaceuticals Highlights Strategic Priorities for 2022 | |
| 2022 | Atea Pharmaceuticals Highlights Strategic Priorities for 2022 | |
| 2022 | Atea Pharmaceuticals, Inc. Provides an Update on the Company’s Clinical Developmen.. | |
| 2022 | North American Morning Briefing: Stock Futures -2- | |
| 2022 | Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference | |
| 2021 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to S.. | |
| 2021 | Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to N.. | |
| 2021 | Atea Pharmaceuticals to Be Added to Nasdaq Biotech Index | |
| 2021 | Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index | |
| 2021 | Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i.. | |
| 2021 | Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i.. | |
| 2021 | Roche: feu vert européen pour le tocilizumab contre le Covid-19 |  |
| 2021 | Atea Pharmaceuticals, Inc. : Regulation FD Disclosure (form 8-K) | |
| 2021 | Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference | |
| 2021 | Health Care Stocks Manage Modest Gains Wednesday | |
| 2021 | Top Midday Decliners | |
| 2021 | Health Care Stocks Moderately Higher This Afternoon | |
| 2021 | Global markets live: Tesla, Experian, Roche, Activision, Amazon... | |
| 2021 | Bourse Zurich: le SMI poursuit sur la voie des records | |
| 2021 | Atea Pharma Shares Drop 16% After Collaboration With Roche Terminated | |
| 2021 | Wall Street Set to Open Largely Flat, Stabilizing After Boost From Data, Retail Earning.. | |
| 2021 | Aktien New York Ausblick: Wenig Bewegung - Unternehmensnachrich.. |  |
| 2021 | Top Premarket Decliners | |
| 2021 | Atea Pharmaceuticals to Terminate Roche Collaboration for Development of COVID-19 Oral .. | |
| 2021 | Bourse Zurich: le SMI toujours hésitant à l'approche de la mi-journée | |
| 2021 | L'Europe sans direction, l'inflation britannique pèse sur le Footsie | |
| 2021 | Bourse Zurich: ouverture timide, après le record en clôture de mardi | |
| 2021 | Bourse Zurich: ouverture timide attendue après le record en clôture de mar.. | |
| 2021 | Roche met un terme à son partenariat avec Atea Pharmaceuticals | |
| 2021 | Roche, Atea Pharmaceuticals Cancel COVID-19 Therapy Development Partnership | |
| 2021 | Atea Pharmaceuticals, Inc. : Termination of a Material Definitive Agreement (form 8-K) | |
| 2021 | Roche walks away from Atea partnership to develop COVID-19 pill | |
| 2021 | Atea Pharmaceuticals to Terminate Roche Collaboration for Joint Development of COVID-19.. | |
| 2021 | Atea Pharma says deal to develop COVID-19 pill with Roche terminated | |
| 2021 | Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche | |
| 2021 | Atea Pharmaceuticals, Inc. Provides Update on Strategic Collaboration with Roche | |
| 2021 | ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition.. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
